Cytokine and CAM Antagonists
|
|
|
- Scot Lambert
- 8 years ago
- Views:
Transcription
1 Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical edit Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical edit criteria rules Logic diagram: a visual depiction of the clinical edit criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes) References: clinical publications and sources relevant to this clinical edit te: Click the hyperlink to navigate directly to that section. Cimzia (Certolizumab pegol) Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical edit Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical edit criteria rules Logic diagram: a visual depiction of the clinical edit criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes) References: clinical publications and sources relevant to this clinical edit te: Click the hyperlink to navigate directly to that section. July 1, 2014 Copyright 2014 Health Information Designs, LLC 1
2 Kineret (Anakinra) Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical edit Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical edit criteria rules Logic diagram: a visual depiction of the clinical edit criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes) References: clinical publications and sources relevant to this clinical edit te: Click the hyperlink to navigate directly to that section. Orencia (Abatacept) Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical edit Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical edit criteria rules Logic diagram: a visual depiction of the clinical edit criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes) References: clinical publications and sources relevant to this clinical edit te: Click the hyperlink to navigate directly to that section. Simponi (Golimumab) Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical edit Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical edit criteria rules Logic diagram: a visual depiction of the clinical edit criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes) References: clinical publications and sources relevant to this clinical edit te: Click the hyperlink to navigate directly to that section. July 1, 2014 Copyright 2014 Health Information Designs, LLC 2
3 Stelara (Ustekinumab) Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical edit Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical edit criteria rules Logic diagram: a visual depiction of the clinical edit criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes) References: clinical publications and sources relevant to this clinical edit te: Click the hyperlink to navigate directly to that section. Xeljanz (Tofacitinib) Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical edit Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical edit criteria rules Logic diagram: a visual depiction of the clinical edit criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes) References: clinical publications and sources relevant to this clinical edit te: Click the hyperlink to navigate directly to that section. Revision tes N/A, initial publication July 1, 2014 Copyright 2014 Health Information Designs, LLC 3
4 Actemra (Tocilizumab) Drugs Requiring Prior Authorization Actemra Label Name GCN ACTEMRA 162MG/0.9ML SYRINGE July 1, 2014 Copyright 2014 Health Information Designs, LLC 4
5 Actemra (Tocilizumab) Clinical Edit Criteria Logic 1. Does the client have a diagnosis of rheumatoid arthritis in the last 730 days? [] Go to #2 [] Go to #5 2. Is the client greater than or equal to ( ) 18 years of age? [] Go to #3 [] Deny 3. Does the client have 1 claim for a TNF blocker in the last 180 days? [] Go to #7 [] Go to #4 4. Does the client have a contraindication to or is the client non-responsive to a TNF-blocker? [manual] [] Go to #7 [] Deny 5. Does the client have a diagnosis of polyarticular idiopathic arthritis or systemic juvenile idiopathic arthritis in the last 730 days? [] Go to #6 [] Deny 6. Is the client 2 years of age? [] Go to #7 [] Deny 7. Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? [] Deny [] Go to #8 8. Does the client have 1 claim for a TNF modifier in the last 14 days? [] Deny [] Approve (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 5
6 Actemra (Tocilizumab) Clinical Edit Criteria Logic Diagram Step 1 Does the client have a diagnosis of rheumatoid arthritis in the last 730 days? Step 5 Does the client have a diagnosis of polyarticular idiopathic arthritis or systemic juvenile idiopathic arthritis in the last 730 days? Step 6 Is the client 2 years of age? Step 2 Is the client 18 years of age? Step 3 Does the client have 1 claim for a TNF blocker in the last 180 days? Step 7 Does the client have an active infection (including Hepatitis B virus and/or tuberculosis)? Step 4 Step 8 Does the client have a contraindication to or is the client nonresponsive to a TNFblocker? [manual] Does the client have 1 claim for a TNF modifier in the last 14 days? Approve Request (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 6
7 Actemra (Tocilizumab) Clinical Edit Criteria Supporting Tables Step 2 (diagnosis of Rheumatoid Arthritis) Look back timeframe: 730 days ICD-9 Code Description RHEUMATOID ARTHRITIS ICD-10 Code Description M06.8 OTHER SPECIFIED RHEUMATOID ARTHRITIS M06.9 RHEUMATOID ARTHRITIS, UNSPECIFIED Step 4 (prior therapy with a TNF blocker) Look back timeframe: 180 days GCN Description CIMZIA 200MG VIAL KIT CIMZIA 200MG/ML SYRINGE KIT ENBREL 25MG KIT ENBREL 25MG/0.5ML SYRINGE ENBREL 50MG/ML SURECLICK SYRINGE ENBREL 50MG/ML SYRINGE HUMIRA 20MG/0.4ML SYRINGE HUMIRA 40MG/0.8ML PEN HUMIRA 40MG/0.8ML SYRINGE HUMIRA STARTER PACK REMICADE 100MG VIAL SIMPONI 100MG/ML PEN INJECTOR SIMPONI 100MG/ML SYRINGE SIMPONI 50MG/0.5ML PEN INJECTOR SIMPONI 50MG/0.5ML SYRINGE SIMPONI ARIA 50MG/4ML VIAL July 1, 2014 Copyright 2014 Health Information Designs, LLC 7
8 Actemra (Tocilizumab) Clinical Edit Criteria Supporting Tables Step 6 (diagnosis of Polyarticular Idiopathic Arthritis or Systemic Juvenile Idiopathic Arthritis) Look back timeframe: 730 days ICD-9 Code Description JUVENILE CHRONIC POLYARTHRITIS ICD-10 Code Description M08.0 UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS M08.2 JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET MO8.3 JUVENILE RHEUMATOID POLYARTHRITIS (SERONEGATIVE) MO8.4 PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS Step 8 (Active infection) Look back timeframe: 180 days ICD-9 Code Description VIRAL HEPATITIS B WITH HEPATIC COMA VIRAL HEPATITIS B WITHOUT MENTION OF HEPATIC COMA 010 PRIMARY TUBERCULOUS INFECTION 011 PULMONARY TUBERCULOSIS 012 OTHER RESPIRATORY TUBERCULOSIS PNEUMONIA IN ASPERGILLOSIS PNEUMOCYSTOSIS ICD-10 Code Description B16 ACUTE HEPATITIS B B18.0 CHRONIC VIRAL HEPATITIS B WITH DELTA-AGENT B18.1 CHRONIC VIRAL HEPATITIS B WITHOUT DELTA-AGENT B19.1 UNSPECIFIED VIRAL HEPATITIS B A15 RESPIRATORY TUBERCULOSIS B44 ASPERGILLOSIS B59 PNEUMOCYSTOSIS July 1, 2014 Copyright 2014 Health Information Designs, LLC 8
9 Actemra (Tocilizumab) Clinical Edit Criteria Supporting Tables Step 9 (therapy with a TNF modifier) Look back timeframe: 14 days GCN Description ARZERRA 1000MG/50ML VIAL ARZERRA 100MG/5ML VIAL KINERET 100MG/0.67ML SYRINGE ORENCIA 125MG/ML SYRINGE ORENCIA 250MG VIAL RITUXAN 10MG/ML VIAL July 1, 2014 Copyright 2014 Health Information Designs, LLC 9
10 Cimzia (Certolizumab pegol) Drugs Requiring Prior Authorization Cimzia Label Name GCN CIMZIA 200MG VIAL KIT CIMZIA 200MG/ML STARTER KIT July 1, 2014 Copyright 2014 Health Information Designs, LLC 10
11 Cimzia (Certolizumab pegol) Clinical Edit Criteria Logic 1. Does the client have a diagnosis of ankylosing spondylitis, Crohn s disease, psoriatic arthritis and/or rheumatoid arthritis in the last 730 days? [] Go to #2 [] Deny 2. Is the client greater than or equal to ( ) 18 years of age? [] Go to #3 [] Deny 3. Does the client have a history of a demyelinating disease (multiple sclerosis, optic neuritis, Guillain-Barre syndrome) in the last 365 days? [] Deny [] Go to #4 4. Does the client have a history of heart failure in the last 365 days? [] Deny [] Go to #5 5. Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? [] Deny [] Go to #6 6. Does the client have a history of hematologic abnormalities in the last 60 days? [] Deny [] Approve (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 11
12 Cimzia (Certolizumab pegol) Clinical Edit Criteria Logic Diagram Step 1 Does the client have a diagnosis of ankylosing spondylitis, Crohn s diseas, psoriatic arthritis and/ or rheumatoid arthritis in the last 730 days? Step 2 Is the client 18 years of age? Step 3 Does the client have a history of demyelinating disease in the last 365 days? Step 4 Does the client have a history of heart failure in the last 365 days? Step 5 Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? Step 6 Does the client have a history of hematologic abnormalities in the last 60 days? Approve Request (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 12
13 Cimzia (Certolizumab pegol) Clinical Edit Criteria Supporting Tables Step 1 (diagnosis of Ankylosing spondylitis, Crohn s disease, psoriatic arthritis and/or rheumatoid arthritis) Look back timeframe: 730 days ICD-9 Code Description ANKYLOSING SPONDYLITIS 555 REGIONAL ENTERITIS REGIONAL ENTERITIS OF SMALL INTESTINE REGIONAL ENTERITIS OF LARGE INTESTINE REGIONAL ENTERITIS OF SMALL INTESTINE WITH LARGE INTESTINE REGIONAL ENTRITIS OF UNSPECIFIED SITE PSORIATIC ARTHROPATHY RHEUMATOID ARTHRITIS ICD-10 Code Description M45 ANKYLOSING SPONDYLITIS M45.0 ANKYLOSING SPONDYLITIS OF MULTIPLE SITES IN SPINE M45.1 ANKYLOSING SPONDYLITIS OF OCCIPITO-ATLANTO-AXIAL REGION M45.2 ANKYLOSING SPONDYLITIS OF CERVICAL REGION M45.3 ANKYLOSING SPONDYLITIS OF CERVICOTHORACIC REGION M45.4 ANKYLOSING SPONDYLITIS OF THORACIC REGION M45.5 ANKYLOSING SPONDYLITIS OF THORACOLUMBAR REGION M45.6 ANKYLOSING SPONDYLITIS LUMBAR REGION M45.7 ANKYLOSING SPONDYLITIS OF LUMBOSACRAL REGION M45.8 ANKYLOSING SPONDYLITIS SACRAL AND SACROCOCCYGEAL REGION M45.9 ANKYLOSING SPONDYLITIS OF UNSPECIFIED SITES IN SPINE K50 CROHN S DISEASE K50.0 CROHN S DISEASE OF SMALL INTESTINE K50.1 CROHN S DISEASE OF LARGE INTESTINE K50.8 CROHN S DISEASE OF BOTH SMALL AND LARGE INTESTINE K50.9 CROHN S DISEASE, UNSPECIFIED L40.5 ARTHROPATHIC PSORIASIS M06.8 OTHER SPECIFIED RHEUMATOID ARTHRITIS M06.9 RHEUMATOID ARTHRITIS, UNSPECIFIED July 1, 2014 Copyright 2014 Health Information Designs, LLC 13
14 Cimzia (Certolizumab pegol) Clinical Edit Criteria Supporting Tables Step 3 (history of demyelinating disease) Look back timeframe: 365 days ICD-9 Code Description 340 MULTIPLE SCLEROSIS OPTIC NEURITIS GUILLAIN-BARRE SYNDROME ICD-10 Code Description G35 MULTIPLE SCLEROSIS H46 OPTIC NEURITIS H46.0 OPTIC PAPILLITIS H46.1 RETROBULBAR NEURITIS H46.2 NUTRITIONAL OPTIC NEUROPATHY H46.3 TOXIC OPTIC NEUROPATHY H46.8 OTHER OPTIC NEURITIS H46.9 UNSPECIFIED OPTIC NEURITIS G61.0 GUILLAIN-BARRE SYNDROME Step 4 (history of heart failure) Look back timeframe: 365 days ICD-9 Code Description 428 HEART FAILURE LEFT HEART FAILURE LEFT HEART FAILURE SYSTOLIC HEART FAILURE SYSTOLIC HEART FAILURE, UNSPECIFIED ACUTE SYSTOLIC HEART FAILURE CHRONIC SYSTOLIC HEART FAILURE ACUTE ON CHRONIC SYSTOLIC HEART FAILURE DIASTOLIC HEART FAILURE DIASTOLIC HEART FAILURE, UNSPECIFIED ACUTE DIASTOLIC HEART FAILURE CHRONIC DIASTOLIC HEART FAILURE July 1, 2014 Copyright 2014 Health Information Designs, LLC 14
15 ICD-9 Code Description Step 4 (history of heart failure) Look back timeframe: 365 days ACUTE ON CHRONIC DIASTOLIC HEART FAILURE COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE, UNSPECIFIED ACUTE COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE ACUTE ON CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE HEART FAILURE, UNSPECIFIED ICD-10 Code I50 Description HEART FAILURE I50.1 LEFT VENTRICULAR FAILURE I50.2 SYSTOLIC (CONGESTIVE) HEART FAILURE I50.20 UNSPECIFIED SYSTOLIC (CONGESTIVE) HEART FAILURE I50.21 ACUTE SYSTOLIC (CONGESTIVE) HEART FAILURE I50.22 CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE I50.23 ACUTE ON CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE I50.3 DIASTOLIC (CONGESTIVE) HEART FAILURE I50.30 UNSPECIFIED DIASTOLIC (CONGESTIVE) HEART FAILURE I50.31 ACUTE DIASTOLIC (CONGESTIVE) HEART FAILURE I50.32 CHRONIC DIASTOLIC (CONGESTIVE) HEART FAILURE I50.33 ACUTE ON CHRONIC DIASTOLIC (CONGESTIVE) HEART FAILURE I50.4 COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE I50.40 UNSPECIFIED COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE I50.41 ACUTE COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE I50.42 CHRONIC COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE I50.43 ACUTE ON CHRONIC COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE I50.9 HEART FAILURE, UNSPECIFIED July 1, 2014 Copyright 2014 Health Information Designs, LLC 15
16 Cimzia (Certolizumab pegol) Clinical Edit Criteria Supporting Tables Step 5 (Active infection) Look back timeframe: 180 days ICD-9 Code Description VIRAL HEPATITIS B WITH HEPATIC COMA VIRAL HEPATITIS B WITHOUT MENTION OF HEPATIC COMA 010 PRIMARY TUBERCULOUS INFECTION 011 PULMONARY TUBERCULOSIS 012 OTHER RESPIRATORY TUBERCULOSIS PNEUMONIA IN ASPERGILLOSIS PNEUMOCYSTOSIS ICD-10 Code Description B16 ACUTE HEPATITIS B B18.0 CHRONIC VIRAL HEPATITIS B WITH DELTA-AGENT B18.1 CHRONIC VIRAL HEPATITIS B WITHOUT DELTA-AGENT B19.1 UNSPECIFIED VIRAL HEPATITIS B A15 RESPIRATORY TUBERCULOSIS B44 ASPERGILLOSIS B59 PNEUMOCYSTOSIS Step 6 (history of hematologic abnormalities) Look back timeframe: 60 days ICD-9 Code Description PANCYTOPENIA CONSTITUTIONAL APLASTIC ANEMIA OTHER SPECIFIED APLASTIC ANEMIAS APLASTIC ANEMIA, UNSPECIFIED DECREASED WHITE BLOOD CELL COUNT PRIMARY THROMBOCYTOPENIA SECONDARY THROMBOCYTOPENIA THROMBOCYTOPENIA, UNSPECIFIED NEUTROPENIA July 1, 2014 Copyright 2014 Health Information Designs, LLC 16
17 Step 6 (history of hematologic abnormalities) Look back timeframe: 60 days ICD-10 Code Description D61.81 PANCYTOPENIA D61.0 CONSTITUTIONAL APLASTIC ANEMIA D61.2 APLASTIC ANEMIA DUE TO OTHER EXTERNAL AGENTS D61.3 IDIOPATHIC APLASTIC ANEMIA D61.9 APLASTIC ANEMIA, UNSPECIFIED D72.81 DECREASED WHITE BLOOD CELL COUNT D69.4 OTHER PRIMARY THROMBOCYTOPENIA D69.5 SECONDARY THROMBOCYTOPENIA D69.6 THROMBOCYTOPENIA, UNSPECIFIED D70 NEUTROPENIA D70.0 CONGENITAL AGRANULOCYTOSIS D70.1 AGRANULOCYTOSIS SECONDARY TO CANCER CHEMOTHERAPY D70.2 OTHER DRUG-INDUCED AGRANULOCYTOSIS D70.3 NEUTROPENIA DUE TO INFECTION D70.4 CYCLIC NEUTROPENIA D70.8 OTHER NEUTROPENIA D70.9 NEUTROPENIA, UNSPECIFIED July 1, 2014 Copyright 2014 Health Information Designs, LLC 17
18 Kineret (Anakinra) Drugs Requiring Prior Authorization Kineret Label Name GCN KINERET 100MG/0.67ML SYRINGE July 1, 2014 Copyright 2014 Health Information Designs, LLC 18
19 Kineret (Anakinra) Clinical Edit Criteria Logic 1. Does the client have a diagnosis of rheumatoid arthritis in the last 730 days? [] Go to #2 [] Go to #5 2. Is the client greater than or equal to ( ) 18 years of age? [] Go to #3 [] Deny 3. Does the client have 1 claim for a disease modifying antirheumatic drug (DMARD) in the last 180 days? [] Go to #6 [] Go to #4 4. Does the client have a contraindication to or is the client non-responsive to DMARDs? [manual] [] Go to #6 [] Deny 5. Does the client have a diagnosis of cryopyrin-associated periodic syndrome (CAPS) in the last 730 days? [] - Go to #6 [] - Deny 6. Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? [] Deny [] Go to #7 7. Does the client have 1 claim for a TNF blocker in the last 14 days? [] Deny [] Approve (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 19
20 Kineret (Anakinra) Clinical Edit Criteria Logic Diagram Step 1 Step 2 Step 3 Step 4 Does the client have a diagnosis of rheumatoid arthritis in the last 730 days? Is the client 18 years of age? Does the client have 1 claim for a DMARD in the last 180 days? Does the client have a contraindication to or is the client nonresponsive to DMARDs? [manual] Step 5 Does the client have a diagnosis of cryopyrinassociated periodic syndrome in the last 730 days? Step 6 Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? Step 7 Does the client have 1 claim for a TNF blocker in the last 14 days? Approve Request (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 20
21 Kineret (Anakinra) Clinical Edit Criteria Supporting Tables Step 1 (diagnosis of rheumatoid arthritis) Look back timeframe: 730 days ICD-9 Code Description RHEUMATOID ARTHRITIS ICD-10 Code Description M06.8 OTHER SPECIFIED RHEUMATOID ARTHRITIS M06.9 RHEUMATOID ARTHRITIS, UNSPECIFIED Step 3 (history of DMARD) Look back timeframe: 180 days Label Name GCN AZASAN 75 MG TABLET AZASAN 100 MG TABLET AZATHIOPRINE 50 MG TABLET CYCLOSPORINE 25 MG CAPSULE CYCLOSPORINE MODIFIED 25 MG CYCLOSPORINE 50 MG CAPSULE CYCLOSPORINE 100 MG CAPSULE CYCLOSPORINE MODIFIED 100 MG CYCLOSPORINE 100 MG/ML CYCLOSPORINE 100 MG/ML HYDROXYCHLOROQUINE 200 MG TABLET LEFLUNOMIDE 10 MG TABLET LEFLUNOMIDE 20 MG TABLET METHOTREXATE 2.5 MG TABLET METHOTREXATE 2.5 MG TABLET SULFASALAZINE 500 MG TABLET SULFASALAZINE DR 500 MG TABLET July 1, 2014 Copyright 2014 Health Information Designs, LLC 21
22 Kineret (Anakinra) Clinical Edit Criteria Supporting Tables Step 5 (diagnosis of cryopyrin-associated periodic syndrome) Look back timeframe: 730 days ICD-9 Code Description OTHER SPECIFIED CONGENITAL ANOMALIES ICD-10 Code Description Q89.8 OTHER SPECIFIED CONGENITAL MALFORMATIONS Step 6 (active infection) Look back timeframe: 180 days ICD-9 Code Description VIRAL HEPATITIS B WITH HEPATIC COMA VIRAL HEPATITIS B WITHOUT MENTION OF HEPATIC COMA 010 PRIMARY TUBERCULOUS INFECTION 011 PULMONARY TUBERCULOSIS 012 OTHER RESPIRATORY TUBERCULOSIS PNEUMONIA IN ASPERGILLOSIS PNEUMOCYSTOSIS ICD-10 Code Description B16 ACUTE HEPATITIS B B18.0 CHRONIC VIRAL HEPATITIS B WITH DELTA-AGENT B18.1 CHRONIC VIRAL HEPATITIS B WITHOUT DELTA-AGENT B19.1 UNSPECIFIED VIRAL HEPATITIS B A15 RESPIRATORY TUBERCULOSIS B44 ASPERGILLOSIS B59 PNEUMOCYSTOSIS July 1, 2014 Copyright 2014 Health Information Designs, LLC 22
23 Kineret (Anakinra) Clinical Edit Criteria Supporting Tables Step 4 (prior therapy with a TNF blocker) Look back timeframe: 14 days GCN Description CIMZIA 200MG VIAL KIT CIMZIA 200MG/ML SYRINGE KIT ENBREL 25MG KIT ENBREL 25MG/0.5ML SYRINGE ENBREL 50MG/ML SURECLICK SYRINGE ENBREL 50MG/ML SYRINGE HUMIRA 20MG/0.4ML SYRINGE HUMIRA 40MG/0.8ML PEN HUMIRA 40MG/0.8ML SYRINGE HUMIRA STARTER PACK REMICADE 100MG VIAL SIMPONI 100MG/ML PEN INJECTOR SIMPONI 100MG/ML SYRINGE SIMPONI 50MG/0.5ML PEN INJECTOR SIMPONI 50MG/0.5ML SYRINGE SIMPONI ARIA 50MG/4ML VIAL July 1, 2014 Copyright 2014 Health Information Designs, LLC 23
24 Orencia (Abatacept) Drugs Requiring Prior Authorization Orencia Label Name GCN ORENCIA 125 MG/ML SYRINGE ORENCIA 250 MG VIAL July 1, 2014 Copyright 2014 Health Information Designs, LLC 24
25 Orencia (Abatacept) Clinical Edit Criteria Logic 1. Does the client have a diagnosis of rheumatoid arthritis in the last 730 days? [] Go to #2 [] Go to #3 2. Is the client greater than or equal to ( ) 18 years of age? [] Go to #5 [] Deny 3. Does the client have a diagnosis of polyarticular idiopathic arthritis or systemic juvenile idiopathic arthritis in the last 730 days? [] Go to #4 [] Deny 4. Is the client 6 years of age? [] Go to #5 [] Deny 5. Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? [] Deny [] Go to #6 6. Does the client have 1 claim for a TNF blocker in the last 14 days? [] Deny [] Approve (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 25
26 Orencia (Abatacept) Clinical Edit Criteria Logic Diagram Step 1 Step 2 Does the client have a diagnosis of rheumatoid arthritis in the last 730 days? Is the client 18 years of age? Step 3 Step 5 Does the client have a diagnosis of polyarticular idiopathic arthritis or systemic juvenile idiopathic arthritis in the last 730 days? Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? Step 4 Step 6 Is the client 6 years of age? Does the client have 1 claim for a TNF blocker in the last 14 days? Approve Request (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 26
27 Orencia (Abatacept) Clinical Edit Criteria Supporting Tables Step 1 (diagnosis of rheumatoid arthritis) Look back timeframe: 730 days ICD-9 Code Description RHEUMATOID ARTHRITIS ICD-10 Code Description M06.8 OTHER SPECIFIED RHEUMATOID ARTHRITIS M06.9 RHEUMATOID ARTHRITIS, UNSPECIFIED Step 3 (diagnosis of polyarticular idiopathic arthritis or systemic juvenile idiopathic arthritis) Look back timeframe: 730 days ICD-9 Code Description JUVENILE CHRONIC POLYARTHRITIS ICD-10 Code Description M08.0 UNSPECIFIED JUVENILE RHEUMATOID ARTHRITIS MO8.2 JUVENILE RHEUMATOID ARTHRITIS WITH SYSTEMIC ONSET M08.3 JUVENILE RHEUMATOID POLYARTHRITIS (SERONEGATIVE) M08.4 PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS July 1, 2014 Copyright 2014 Health Information Designs, LLC 27
28 Orencia (Abatacept) Clinical Edit Criteria Supporting Tables Step 5 (active infection) Look back timeframe: 180 days ICD-9 Code Description VIRAL HEPATITIS B WITH HEPATIC COMA VIRAL HEPATITIS B WITHOUT MENTION OF HEPATIC COMA 010 PRIMARY TUBERCULOUS INFECTION 011 PULMONARY TUBERCULOSIS 012 OTHER RESPIRATORY TUBERCULOSIS PNEUMONIA IN ASPERGILLOSIS PNEUMOCYSTOSIS ICD-10 Code Description B16 ACUTE HEPATITIS B B18.0 CHRONIC VIRAL HEPATITIS B WITH DELTA-AGENT B18.1 CHRONIC VIRAL HEPATITIS B WITHOUT DELTA-AGENT B19.1 UNSPECIFIED VIRAL HEPATITIS B A15 RESPIRATORY TUBERCULOSIS B44 ASPERGILLOSIS B59 PNEUMOCYSTOSIS Step 4 (prior therapy with a TNF blocker) Look back timeframe: 14 days GCN Description CIMZIA 200MG VIAL KIT CIMZIA 200MG/ML SYRINGE KIT ENBREL 25MG KIT ENBREL 25MG/0.5ML SYRINGE ENBREL 50MG/ML SURECLICK SYRINGE ENBREL 50MG/ML SYRINGE HUMIRA 20MG/0.4ML SYRINGE HUMIRA 40MG/0.8ML PEN HUMIRA 40MG/0.8ML SYRINGE July 1, 2014 Copyright 2014 Health Information Designs, LLC 28
29 Step 4 (prior therapy with a TNF blocker) Look back timeframe: 14 days GCN Description HUMIRA STARTER PACK REMICADE 100MG VIAL SIMPONI 100MG/ML PEN INJECTOR SIMPONI 100MG/ML SYRINGE SIMPONI 50MG/0.5ML PEN INJECTOR SIMPONI 50MG/0.5ML SYRINGE SIMPONI ARIA 50MG/4ML VIAL July 1, 2014 Copyright 2014 Health Information Designs, LLC 29
30 Simponi (Golimumab) Drugs Requiring Prior Authorization Simponi Label Name GCN SIMPONI 100 MG/ML PEN INJECTOR SIMPONI 100 MG/ML SYRINGE SIMPONI 50 MG/0.5 ML PEN INJECTOR SIMPONI 50MG/0.5 ML SYRINGE SIMPONI ARIA 50 MG/4 ML VIAL July 1, 2014 Copyright 2014 Health Information Designs, LLC 30
31 Simponi (Golimumab) Clinical Edit Criteria Logic 1. Is the client greater than or equal to ( ) 18 years of age? [] Go to #2 [] Deny 2. Does the client have a diagnosis of rheumatoid arthritis in the last 730 days? [] Go to #4 [] Go to #3 3. Does the client have a diagnosis of ankylosing spondylitis, psoriatic arthritis and/or ulcerative colitis in the last 730 days? [] Go to #5 [] Deny 4. Does the client have 1 claim for methotrexate in the last 60 days? [] Go to #5 [] Deny 5. Does the client have a history of heart failure in the last 365 days? [] Deny [] Go to #6 6. Does the client have a history of demyelinating disease (multiple sclerosis, optic neuritis and/or Guillain-Barre syndrome) in the last 365 days? [] Deny [] Go to #7 7. Does the client have a history of hematologic abnormalities in the last 180 days? [] Deny [] Go to #8 8. Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? [] Deny [] (Approve 365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 31
32 Simponi (Golimumab) Clinical Edit Criteria Logic Diagram Step 1 Step 2 Step 4 Is the client 18 years of age? Does the client have a diagnosis of rheumatoid arthritis in the last 730 days? Does the client have 1 claim for methotrexate in the last 60 days? Step 3 Does the client have a diagnosis of ankylosing spondylitis, psoriatic arthritis and/ or ulcerative colitis in the last 730 days? Step 5 Does the client have a history of heart failure in the last 365 days? Step 6 Does the client have a history of demyelinating disease in the last 365 days? Step 7 Does the client have a history of hematologic abnormalities in the last 180 days? Step 8 Approve Request (365 days) Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? July 1, 2014 Copyright 2014 Health Information Designs, LLC 32
33 Simponi (Golimumab) Clinical Edit Criteria Supporting Tables Step 2 (diagnosis of rheumatoid arthritis) Look back timeframe: 730 days ICD-9 Code Description RHEUMATOID ARTHRITIS ICD-10 Code Description M06.8 OTHER SPECIFIED RHEUMATOID ARTHRITIS M06.9 RHEUMATOID ARTHRITIS, UNSPECIFIED Step 3 (diagnosis of ankylosing spondylitis, psoriatic arthritis and/or ulcerative colitis) Look back timeframe: 730 days ICD-9 Code Description ANKYLOSING SPONDYLITIS PSORIATIC ARTHROPATHY 556 ULCERATIVE ENTEROCOLITIS ULCERATIVE (CHRONIC) ENTEROCOLITIS ULCERATIVE (CHRONIC) ILEOCOLITIS ULCERATIVE (CHRONIC) PROCTITIS ULCERATIVE (CHRONIC) PROCTOSIGMOIDITIS PSEUDOPOLYPOSIS OF COLON LEFT-SIDED ULCERATIVE (CHRONIC) COLITIS UNIVERSAL ULCERATIVE (CHRONIC) COLITIS OTHER ULCERATIVE COLITIS ULCERATIVE COLITIS, UNSPECIFIED ICD-10 Code Description M45 ANKYLOSING SPONDYLITIS M45.0 ANKYLOSING SPONDYLITIS OF MULTIPLE SITES IN SPINE M45.1 ANKYLOSING SPONDYLITIS OF OCCIPITO-ATLANTO-AXIAL REGION M45.2 ANKYLOSING SPONDYLITIS OF CERVICAL REGION M45.3 ANKYLOSING SPONDYLITIS OF CERVICOTHORACIC REGION M45.4 ANKYLOSING SPONDYLITIS OF THORACIC REGION July 1, 2014 Copyright 2014 Health Information Designs, LLC 33
34 Step 3 (diagnosis of ankylosing spondylitis, psoriatic arthritis and/or ulcerative colitis) Look back timeframe: 730 days ICD-10 Code Description M45.5 ANKYLOSING SPONDYLITIS OF THORACOLUMBAR REGION M45.6 ANKYLOSING SPONDYLITIS LUMBAR REGION M45.7 ANKYLOSING SPONDYLITIS OF LUMBOSACRAL REGION M45.8 ANKYLOSING SPONDYLITIS SACRAL AND SACROCOCCYGEAL REGION M45.9 ANKYLOSING SPONDYLITIS OF UNSPECIFIED SITES IN SPINE L40.5 ARTHROPATHIC PSORIASIS K51 ULCERATIVE COLITIS K51.0 ULCERATIVE (CHRONIC) PANCOLITIS K51.2 ULCERATIVE (CHRONIC) PROCTITIS K51.3 ULCERATIVE (CHRONIC) RECTOSIGMOIDITIS K51.4 INFLAMMATORY POLYPS OF COLON K51.5 LEFT SIDED COLITIS K51.8 OTHER ULCERATIVE COLITIS K51.9 ULCERATIVE COLITIS, UNSPECIFIED Step 4 (prior therapy with methotrexate) Look back timeframe: 60 days GCN Description METHOTREXATE 2.5 MG TABLET METHOTREXATE 2.5 MG TABLET Step 5 (history of heart failure) Look back timeframe: 365 days ICD-9 Code Description 428 HEART FAILURE LEFT HEART FAILURE LEFT HEART FAILURE July 1, 2014 Copyright 2014 Health Information Designs, LLC 34
35 ICD-9 Code Description SYSTOLIC HEART FAILURE Step 5 (history of heart failure) Look back timeframe: 365 days SYSTOLIC HEART FAILURE, UNSPECIFIED ACUTE SYSTOLIC HEART FAILURE CHRONIC SYSTOLIC HEART FAILURE ACUTE ON CHRONIC SYSTOLIC HEART FAILURE DIASTOLIC HEART FAILURE DIASTOLIC HEART FAILURE, UNSPECIFIED ACUTE DIASTOLIC HEART FAILURE CHRONIC DIASTOLIC HEART FAILURE ACUTE ON CHRONIC DIASTOLIC HEART FAILURE COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE, UNSPECIFIED ACUTE COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE ACUTE ON CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE HEART FAILURE, UNSPECIFIED ICD-10 Code I50 Description HEART FAILURE I50.1 LEFT VENTRICULAR FAILURE I50.2 SYSTOLIC (CONGESTIVE) HEART FAILURE I50.20 UNSPECIFIED SYSTOLIC (CONGESTIVE) HEART FAILURE I50.21 ACUTE SYSTOLIC (CONGESTIVE) HEART FAILURE I50.22 CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE I50.23 ACUTE ON CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE I50.3 DIASTOLIC (CONGESTIVE) HEART FAILURE I50.30 UNSPECIFIED DIASTOLIC (CONGESTIVE) HEART FAILURE I50.31 ACUTE DIASTOLIC (CONGESTIVE) HEART FAILURE I50.32 CHRONIC DIASTOLIC (CONGESTIVE) HEART FAILURE I50.33 ACUTE ON CHRONIC DIASTOLIC (CONGESTIVE) HEART FAILURE I50.4 COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE I50.40 UNSPECIFIED COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE I50.41 ACUTE COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE I50.42 CHRONIC COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE July 1, 2014 Copyright 2014 Health Information Designs, LLC 35
36 ICD-10 Code Description Step 5 (history of heart failure) Look back timeframe: 365 days I50.43 ACUTE ON CHRONIC COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE I50.9 HEART FAILURE, UNSPECIFIED Step 6 (history of demyelinating disease) Look back timeframe: 365 days ICD-9 Code Description 340 MULTIPLE SCLEROSIS OPTIC NEURITIS GUILLAIN-BARRE SYNDROME ICD-10 Code Description G35 MULTIPLE SCLEROSIS H46 OPTIC NEURITIS H46.0 OPTIC PAPILLITIS H46.1 RETROBULBAR NEURITIS H46.2 NUTRITIONAL OPTIC NEUROPATHY H46.3 TOXIC OPTIC NEUROPATHY H46.8 OTHER OPTIC NEURITIS H46.9 UNSPECIFIED OPTIC NEURITIS G61.0 GUILLAIN-BARRE SYNDROME Step 7 (history of hematologic abnormalities) Look back timeframe: 60 days ICD-9 Code Description PANCYTOPENIA CONSTITUTIONAL APLASTIC ANEMIA OTHER SPECIFIED APLASTIC ANEMIAS APLASTIC ANEMIA, UNSPECIFIED DECREASED WHITE BLOOD CELL COUNT PRIMARY THROMBOCYTOPENIA SECONDARY THROMBOCYTOPENIA THROMBOCYTOPENIA, UNSPECIFIED NEUTROPENIA July 1, 2014 Copyright 2014 Health Information Designs, LLC 36
37 Step 7 (history of hematologic abnormalities) Look back timeframe: 60 days ICD-10 Code Description D61.81 PANCYTOPENIA D61.0 CONSTITUTIONAL APLASTIC ANEMIA D61.2 APLASTIC ANEMIA DUE TO OTHER EXTERNAL AGENTS D61.3 IDIOPATHIC APLASTIC ANEMIA D61.9 APLASTIC ANEMIA, UNSPECIFIED D72.81 DECREASED WHITE BLOOD CELL COUNT D69.4 OTHER PRIMARY THROMBOCYTOPENIA D69.5 SECONDARY THROMBOCYTOPENIA D69.6 THROMBOCYTOPENIA, UNSPECIFIED D70 NEUTROPENIA D70.0 CONGENITAL AGRANULOCYTOSIS D70.1 AGRANULOCYTOSIS SECONDARY TO CANCER CHEMOTHERAPY D70.2 OTHER DRUG-INDUCED AGRANULOCYTOSIS D70.3 NEUTROPENIA DUE TO INFECTION D70.4 CYCLIC NEUTROPENIA D70.8 OTHER NEUTROPENIA D70.9 NEUTROPENIA, UNSPECIFIED Step 8 (active infection) Look back timeframe: 180 days ICD-9 Code Description VIRAL HEPATITIS B WITH HEPATIC COMA VIRAL HEPATITIS B WITHOUT MENTION OF HEPATIC COMA 010 PRIMARY TUBERCULOUS INFECTION 011 PULMONARY TUBERCULOSIS 012 OTHER RESPIRATORY TUBERCULOSIS PNEUMONIA IN ASPERGILLOSIS PNEUMOCYSTOSIS ICD-10 Code Description B16 ACUTE HEPATITIS B B18.0 CHRONIC VIRAL HEPATITIS B WITH DELTA-AGENT B18.1 CHRONIC VIRAL HEPATITIS B WITHOUT DELTA-AGENT B19.1 UNSPECIFIED VIRAL HEPATITIS B A15 RESPIRATORY TUBERCULOSIS B44 ASPERGILLOSIS July 1, 2014 Copyright 2014 Health Information Designs, LLC 37
38 ICD-10 Code B59 Step 8 (active infection) Look back timeframe: 180 days Description PNEUMOCYSTOSIS Step 4 (prior therapy with a TNF blocker) Look back timeframe: 14 days GCN Description CIMZIA 200MG VIAL KIT CIMZIA 200MG/ML SYRINGE KIT ENBREL 25MG KIT ENBREL 25MG/0.5ML SYRINGE ENBREL 50MG/ML SURECLICK SYRINGE ENBREL 50MG/ML SYRINGE HUMIRA 20MG/0.4ML SYRINGE HUMIRA 40MG/0.8ML PEN HUMIRA 40MG/0.8ML SYRINGE HUMIRA STARTER PACK REMICADE 100MG VIAL July 1, 2014 Copyright 2014 Health Information Designs, LLC 38
39 Stelara (Ustekinumab) Drugs Requiring Prior Authorization Stelara Label Name GCN STELARA 45 MG/0.5 ML SYRINGE STELARA 45 MG/0.5 ML VIAL STELARA 90 MG/ML SYRINGE July 1, 2014 Copyright 2014 Health Information Designs, LLC 39
40 Stelara (Ustekinumab) Clinical Edit Criteria Logic 1. Is the client greater than or equal to ( ) 18 years of age? [] Go to #2 [] Deny 2. Does the client have a diagnosis of plaque psoriasis and/or psoriatic arthritis in the last 730 days? [] Go to #3 [] Deny 3. Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? [] Deny [] Approve (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 40
41 Stelara (Ustekinumab) Clinical Edit Criteria Logic Diagram Step 1 Step 2 Is the client 18 years of age? Does the client have a diagnosis of plaque psoriasis and/or psoriatic arthritis in the last 730 days? Step 3 Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? Approve Request (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 41
42 Stelara (Ustekinumab) Clinical Edit Criteria Supporting Tables Step 2 (diagnosis of plaque psoriasis and/or psoriatic arthritis) Look back timeframe: 730 days ICD-9 Code Description OTHER PSORIASIS PSORIATIC ARTHROPATHY ICD-10 Code Description L40.1 GENERALIZED PUSTULAR PSORIASIS L40.8 OTHER PSORIASIS L40.5 ARTHROPATHIC PSORIASIS Step 3 (active infection) Look back timeframe: 180 days ICD-9 Code Description VIRAL HEPATITIS B WITH HEPATIC COMA VIRAL HEPATITIS B WITHOUT MENTION OF HEPATIC COMA 010 PRIMARY TUBERCULOUS INFECTION 011 PULMONARY TUBERCULOSIS 012 OTHER RESPIRATORY TUBERCULOSIS PNEUMONIA IN ASPERGILLOSIS PNEUMOCYSTOSIS ICD-10 Code Description B16 ACUTE HEPATITIS B B18.0 CHRONIC VIRAL HEPATITIS B WITH DELTA-AGENT B18.1 CHRONIC VIRAL HEPATITIS B WITHOUT DELTA-AGENT B19.1 UNSPECIFIED VIRAL HEPATITIS B A15 RESPIRATORY TUBERCULOSIS B44 ASPERGILLOSIS B59 PNEUMOCYSTOSIS July 1, 2014 Copyright 2014 Health Information Designs, LLC 42
43 Xeljanz (Tofacitinib) Drugs Requiring Prior Authorization Xeljanz Label Name GCN XELJANZ 5 MG TABLET July 1, 2014 Copyright 2014 Health Information Designs, LLC 43
44 Xeljanz (Tofacitinib) Clinical Edit Criteria Logic 1. Is the client greater than or equal to ( ) 18 years of age? [] Go to #2 [] Deny 2. Does the client have a diagnosis of rheumatoid arthritis in the last 730 days? [] Go to #3 [] Deny 3. Is the client 18 years of age? [] Go to #3 [] Deny 4. Does the client have 1 claim for methotrexate in the last 730 days? [] Go to #5 [] Go to #4 5. Does the client have a history of inadequate response or intolerance to methotrexate? [manual] [] Go to #5 [] Deny 6. Does the client have 1 claim for a biological DMARD or potent immunosuppressant in the last 60 days? [] Deny [] Go to #6 7. Does the client have 1 claim for a strong CYP3A4 inducer in the last 60 days? [] Deny [] Go to #7 8. Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? [] Deny [] Approve (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 44
45 Xeljanz (Tofacitinib) Clinical Edit Criteria Logic Diagram Step 1 Is the client 18 years of age? Step 2 Does the client have a diagnosis of rheumatoid arthritis in the last 730 days? Step 3 Does the client have 1 claim for methotrexate in the last 60 days? Step 5 Does the client have 1 claim for a biological DMARD or potent immunosuppressant in the last 60 days? Step 4 Does the client have a history of inadequate response or intolerance to methotrexate? [manual] Step 6 Does the client have 1 claim for a strong CYP3A4 inducer in the last 60 days? Step 8 Does the client have an active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days? Approve Request (365 days) July 1, 2014 Copyright 2014 Health Information Designs, LLC 45
46 Xeljanz (Tofacitinib) Clinical Edit Criteria Supporting Tables Step 2 (diagnosis of rheumatoid arthritis) Look back timeframe: 730 days ICD-9 Code Description RHEUMATOID ARTHRITIS ICD-10 Code Description M06.8 OTHER SPECIFIED RHEUMATOID ARTHRITIS M06.9 RHEUMATOID ARTHRITIS, UNSPECIFIED Step 3 (prior therapy with methotrexate) Look back timeframe: 60 days GCN Description METHOTREXATE 2.5 MG TABLET METHOTREXATE 2.5 MG TABLET Step 5 (prior therapy with a DMARD or potent immunosuppressant) Look back timeframe: 60 days GCN Description KINERET 100 MG/0.67 ML SYRINGE RITUXAN 10 MG/ML VIAL ARZERRA 1000 MG/50ML VIAL ARZERRA 100 MG/5ML VIAL ORENCIA 125 MG/ML SYRING ORENCIA 250 MG VIAL ACTEMRA 162 MG/0.9ML SYRINGE ACTEMRA 200 MG/10ML VIAL ACTEMRA 400 MG/20ML VIAL ACTEMRA 80 MG/4ML VIAL CYCLOSPORINE 25 MG CAPSULE CYCLOSPORINE MODIFIED 25 MG July 1, 2014 Copyright 2014 Health Information Designs, LLC 46
47 Step 5 (prior therapy with a DMARD or potent immunosuppressant) Look back timeframe: 60 days GCN Description CYCLOSPORINE 50 MG CAPSULE CYCLOSPORINE 100 MG CAPSULE CYCLOSPORINE MODIFIED 100 MG CYCLOSPORINE 100 MG/ML CYCLOSPORINE 100 MG/ML AZASAN 100 MG TABLET AZASAN 75 MG TABLET AZATHIOPRINE 50 MG TABLET TACROLIMUS 0.5 MG CAPSULE TACROLIMUS 1 MG CAPSULE TACROLIMUS 5 MG CAPSULE ASTAGRAF XL 0.5 MG CAPSULE ASTAGRAF XL 1 MG CAPSULE ASTAGRAF XL 5 MG CAPSULE MYCOPHENOLATE 250 MG CAPSULE MYCOPHENOLATE 500 MG TABLET CELLCEPT 200 MG/ML ORAL SUSP MYCOPHENOLIC ACID DR 180 MG TAB MYCOPHENOLIC ACID DR 360 MG TAB Step 6 (prior therapy with a strong CYP3A4 inducer) Look back timeframe: 60 days GCN Description PHENYTOIN 100 MG/4 ML SUSPENSION PHENYTOIN 100 MG/4 ML SUSPENSION PHENYTOIN 100 MG/4 ML SUSPENSION PHENYTOIN 50 MG TABLET CHEW PHENYTOIN SOD 100 MG CAPSULE PHENYTOIN SOD EXT 100 MG CAPSULE PHENYTOIN SOD EXT 200 MG CAPSULE PHENYTOIN SOD EXT 300 MG CAPSULE DILANTIN 30 MG KAPSEAL CARBAMAZEPINE 100 MG TAB CHEW CARBAMAZEPINE 100 MG/5 ML SUSPENSION CARBAMAZEPINE 100 MG/5 ML SUSPENSION CARBAMAZEPINE 200 MG TABLET July 1, 2014 Copyright 2014 Health Information Designs, LLC 47
48 Step 6 (prior therapy with a strong CYP3A4 inducer) Look back timeframe: 60 days GCN Description CARBAMAZEPINE 200 MG/10 ML LIQUID CARBAMAZEPINE ER 100 MG CAP CARBAMAZEPINE ER 200 MG CAP CARBAMAZEPINE ER 200 MG TABLET CARBAMAZEPINE ER 300 MG CAP CARBAMAZEPINE ER 400 MG TABLET TEGRETOL XR 100 MG TABLET CARBATROL 200 MG CAPSULE SA CARBATROL 300 MG CAPSULE SA EQUETRO 100 MG CAPSULE EQUETRO 200 MG CAPSULE EQUETRO 300 MG CAPSULE PRIMIDONE 250 MG TABLET PRIMIDONE 50 MG TABLET PHENOBARBITAL 100 MG TABLET PHENOBARBITAL 100 MG TABLET PHENOBARBITAL 15 MG TABLET PHENOBARBITAL 16.2 MG TABLET PHENOBARBITAL 20 MG/5 ML ELIXIR PHENOBARBITAL 30 MG TABLET PHENOBARBITAL 32.4 MG TABLET PHENOBARBITAL 60 MG TABLET PHENOBARBITAL 64.8 MG TABLET PHENOBARBITAL 97.2 MG TABLET RIFAMPIN 150 MG CAPSULE RIFAMPIN 300 MG CAPSULE RIFABUTIN 150 MG CAPSULE XTANDI 40 MG CAPSULE Step 7 (active infection) Look back timeframe: 180 days ICD-9 Code Description VIRAL HEPATITIS B WITH HEPATIC COMA VIRAL HEPATITIS B WITHOUT MENTION OF HEPATIC COMA 010 PRIMARY TUBERCULOUS INFECTION July 1, 2014 Copyright 2014 Health Information Designs, LLC 48
49 Step 7 (active infection) Look back timeframe: 180 days 011 PULMONARY TUBERCULOSIS 012 OTHER RESPIRATORY TUBERCULOSIS PNEUMONIA IN ASPERGILLOSIS PNEUMOCYSTOSIS ICD-10 Code Description B16 ACUTE HEPATITIS B B18.0 CHRONIC VIRAL HEPATITIS B WITH DELTA-AGENT B18.1 CHRONIC VIRAL HEPATITIS B WITHOUT DELTA-AGENT B19.1 UNSPECIFIED VIRAL HEPATITIS B A15 RESPIRATORY TUBERCULOSIS B44 ASPERGILLOSIS B59 PNEUMOCYSTOSIS July 1, 2014 Copyright 2014 Health Information Designs, LLC 49
50 Clinical Edit Criteria References 1. Clinical Pharmacology [online database]. Tampa, FL: Elsevier / Gold Standard, Inc Available at Accessed on July 3, ICD-9-CM Diagnosis Codes, Volume Available at Accessed on July 3, ICD-10-CM Diagnosis Codes, Volume Available at Accessed on July 3, Actemra Prescribing Information. Genetech, Inc. South San Francisco, CA. October Cimzia Prescribing Information. UCB, Inc. Smyrna, GA. October Kineret Prescribing Information. SOBI. Stockholm, Sweden. 7. Orencia Prescribing Information. Bristol-Myers Squibb. Princeton, NJ. December Simponi Prescribing Information. Janssen Biotech, Inc. Horsham, PA. January Stelara Prescribing Information. Janssen Biotech, Inc. Horsham, PA. March Xeljanz Prescribing Information. Pfizer, Inc. New York, New York. May July 1, 2014 Copyright 2014 Health Information Designs, LLC 50
51 Publication History The Publication History records the publication iterations and revisions to this document. tes for the most current revision are also provided in the Revision tes on the first page of this document. Publication Date tes July 1, 2014 Copyright 2014 Health Information Designs, LLC 51
Cytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
Cytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
Immune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists
MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must
CLINICAL POLICY Department: Medical Management Document Name: Rheumatoid & Juvenile Arthritis and Ankylosing Spondylitis Treatments
Page: 1 of 18 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
Rheumatic Diseases, Psoriasis, and Crohn s Disease
Rheumatic Diseases, Psoriasis, and Crohn s Disease What does this handout cover? This handout has information about rheumatic disease, psoriasis, and Crohn s disease. It also has information on how these
Biologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
DISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR RHEUMATOID ARTHRITIS
DISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR RHEUMATOID ARTHRITIS APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE NCQA APPROVED CODES HEDIS
MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and
MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This
Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Actemra (tocilizumab) Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015
2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #337: Tuberculosis Prevention for Psoriasis,Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier National Quality Strategy Domain: Effective Clincal Care
Rheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion
Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment
You can find the PsA treatment support you want. You don t have to do this alone.
For adults with active Psoriatic arthritis (Ps a) There is a way forward. You can find the PsA treatment support you want. You don t have to do this alone. Indication: CIMZIA is approved for the treatment
Evidence-based Management of Rheumatoid Arthritis (2009)
CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance
SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
November 1, 2014 Bulletin #150 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary New Exception Drug Status (EDS) Listings Effective November 1, 2014
You can find the PsA treatment support you want. You don t have to do this alone.
For adults with active Psoriatic arthritis (Ps a) There is a way forward. You can find the PsA treatment support you want. You don t have to do this alone. Indication: CIMZIA is approved for the treatment
Giant Spondylitis and Its Effect on Globlogical Therapy
Cytokine and CAM Antagonists and Related Agents Review 01/22/2010 Copyright 2005-2010 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No
Medicines for Rheumatoid. Arthritis. A Review of the Research for Adults
Medicines for Rheumatoid Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this summary is for you if: Your doctor* has told you that you have rheumatoid (pronounced
MEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion ACTEMRA (AC-TEM-RA) (tocilizumab) Injection, Solution for Subcutaneous Administration Read this Medication Guide before
Methotrexate Dose For Juvenile Rheumatoid Arthritis
Methotrexate Dose For Juvenile Rheumatoid Arthritis should i take methotrexate for my ra methotrexate 50 mg/ml methotrexate sodium 2.5mg tablets what is the usual dosage of methotrexate for ra methotrexate
subcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP
Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity
Brochure More information from http://www.researchandmarkets.com/reports/1383065/ Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Description: Introduction Disease-modifying
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
California SB 486 Needle Disposal Plan for SIMPONI (golimumab)
California SB 486 Needle Disposal Plan for SIMPONI (golimumab) This describes the process in place for the end-of-life management of SIMPONI self-injection devices. SIMPONI (golimumab) is a drug for treatment
Let s talk about Arthritis
Let s talk about Arthritis Osteoarthritis Rheumatoid Arthritis Kam Shojania, MD, FRCPC Clinical Professor and Head, St. Paul s, UBC and VGH Divisions of Rheumatology Slides with thanks to: Cheryl Koehn
Rheumatoid Arthritis Information
Rheumatoid Arthritis Information Definition Rheumatoid arthritis (RA) is a long-term disease that leads to inflammation of the joints and surrounding tissues. It can also affect other organs. Alternative
(THE CHANGING LANDSCAPE)
Updating the therapeutic strategy in RA What is effective, what is changing in daily practice regarding the use of DMARDs and biological agents in the Balkan countries The Greek experience (THE CHANGING
biologics for the treatment of psoriasis
How to contact us The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF tel: 08456 760 076 (01604) 251 620 fax: (01604) 251 621 email: mail@psoriasis-association.org.uk www.psoriasis-association.org.uk
Treatment of Rheumatoid Arthritis in the New Millennium. Neal I. Shparago, D.O., FACP, FACR
Treatment of Rheumatoid Arthritis in the New Millennium Neal I. Shparago, D.O., FACP, FACR What is RA? Symmetric inflammatory polyarthritis Rheumatoid factor positive in 80% Anti-CCP positive in approximately
RHEUMATOLOGY ICD-10 CROSSWALK
RHEUMATOLOGY ICD-10 CROSSWALK ICD is revised periodically and is currently in its tenth edition and will be implemented in the United States on October 1, 2015. There is an annual minor update and three-yearly
SECTION 3. Criteria for Special Authorization of Select Drug Products. Section 3 Criteria for Special Authorization of Select Drug Products
SECTION 3 Criteria for Special Authorization of Select Drug Products Section 3 Criteria for Special Authorization of Select Drug Products CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS The
Drug Therapy Guidelines: Humira (adalimumab)
Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:
REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Methotrexate in the 10MM (US, France, Germany,
Psoriatic arthritis FACTSHEET
1 What is psoriatic arthritis? Psoriatic arthritis (PsA) is a disease where joints around the body become inflamed and sore. It can make moving about difficult and painful. People who have PsA also have
Pharmacotherapy of Autoimmune Disorders
PHARMACY / MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Pharmacotherapy of Autoimmune Disorders Number 5.01.550
Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists
Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and
There is a way forward.
For adults with moderate to severe Rheumatoid Arthritis (RA) There is a way forward. You can find the RA treatment support you want. You don t have to do this alone. Indication: CIMZIA is approved for
Rheumatoid Arthritis:
Rheumatoid Arthritis Update 2014 Mark Hulsey, MD FACR Rheumatoid Arthritis Key Features Symptoms >6 weeks duration Often lasts the remainder of the patient s life Inflammatory synovitis Palpable synovial
Pain is the most common complaint for which most patients seek rheumatologic. Chronic Pain From Rheumatoid Arthritis
PRINTER-FRIENDLY VERSION AVAILABLE AT PAINMEDICINENEWS.COM Chronic Pain From Rheumatoid Arthritis ROLAND STAUD, MD Director, Musculoskeletal Pain Research Professor University of Florida College of Medicine
PART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr REMICADE (Infliximab) This leaflet is part III of a three-part "Product Monograph" published when REMICADE was approved for sale in Canada and is designed specifically
Rheumatoid Arthritis
Rheumatoid Arthritis While rheumatoid arthritis (RA) has long been feared as one of the most disabling types of arthritis, the outlook has dramatically improved for many newly diagnosed patients. Certainly
Medication Guide Enbrel (en-brel) (etanercept)
Medication Guide Enbrel (en-brel) (etanercept) Read the Medication Guide that comes with Enbrel before you start using it and each time you get a refill. There may be new information. This Medication Guide
Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module
Brochure More information from http://www.researchandmarkets.com/reports/2583544/ Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module Description: What the future holds: Over the next few years,
Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional Survey
DOI 10.1007/s40744-015-0011-1 ORIGINAL RESEARCH Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional Survey Dana B. DiBenedetti. Xiaolei Zhou. Maria Reynolds. Sarika Ogale. Jennie
Remicade (infliximab)
DRUG POLICY Remicade (infliximab) Policy Number: 2015D004P Effective Date: 12/1/2015 Table of Contents Page COVERAGE RATIONALE... 1 BENEFIT CONSIDERATIONS... 3 BACKGROUND... 3 CLINICAL EVIDENCE... 4 U.S.
Co-pay assistance organizations offering assistance
Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin
Rheumatoid Arthritis Medicines. A Guide for Adults
Rheumatoid Arthritis Medicines A Guide for Adults Fast Facts Medicines for rheumatoid arthritis (RA) can slow down the disease and reduce damage to joints. They can relieve pain and make it easier to do
Key Findings. Use this report to... The Autoimmune Market Outlook to 2013
Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.
NATIONAL PSORIASIS FOUNDATION SYSTEMIC MEDICATIONS. for psoriasis and psoriatic arthritis including biologics and new oral treatments
NATIONAL PSORIASIS FOUNDATION SYSTEMIC MEDICATIONS for psoriasis and psoriatic arthritis including biologics and new oral treatments Introduction to psoriasis and psoriatic arthritis WHAT IS PSORIASIS?
REMICADE (infliximab)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REMICADE safely and effectively. See full prescribing information for REMICADE. REMICADE (infliximab)
LCD for Erythrocyte Sedimentation Rate (ESR)
LCD for Erythrocyte Sedimentation Rate (ESR) Applicable CPT Code(s): 85651 Sedimentation Rate, Erythrocyte; Non-Automated 85652 Sedimentation Rate, Erythrocyte; Automated ICD-9 Codes that Support Medical
SPECIAL AUTHORIZATION GUIDELINES
91B ALBERTA DRUG BENEFIT LIST SPECIAL AUTHORIZATION GUIDELINES 37BSpecial Authorization Policy 90BDrug Products Eligible for Consideration by Special Authorization Drug Products may be considered for coverage
Psoriatic Arthritis. having psoriatic arthritis.
Psoriatic Arthritis having psoriatic arthritis. Psoriatic arthritis is a chronic disease characterized by a form of inflammation of the skin (psoriasis) and joints (inflammatory arthritis). Psoriasis is
Immune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association
Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell
Critical Issues in School Health Arthritis in the School Setting. Lawrence Zemel MD Tegan Willard RN Connecticut Children s
Critical Issues in School Health Arthritis in the School Setting Lawrence Zemel MD Tegan Willard RN Connecticut Children s Juvenile Rheumatoid Idiopathic Arthritis Definition of JRA (JIA) Persistent arthritis
-------------------------------CONTRAINDICATIONS------------------------------ Sepsis (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Enbrel safely and effectively. See full prescribing information for Enbrel. Enbrel (etanercept) Solution
Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies
Brochure More information from http://www.researchandmarkets.com/reports/1504775/ Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies
Rheumatoid Arthritis. Compiled by Darreck My Healing Oils notes
Rheumatoid Arthritis Compiled by Darreck My Healing Oils notes What is Rheumatoid Arthritis Rheumatoid arthritis (RA) is an autoimmune disease where the body's immune system attacks normal joint tissues,
Arthritis in Older Adults. Ewa Olech, M.D. University of Nevada School of Medicine Las Vegas, NV
Arthritis in Older Adults Ewa Olech, M.D. University of Nevada School of Medicine Las Vegas, NV Objectives Examine the prevalence and course of arthritis in older adults Describe the different types of
RHEUMATOID ARTHRITIS Peek n Peak - 2016
RHEUMATOID ARTHRITIS Peek n Peak - 2016 General characteristics of Epidemiology Clinical manifestations Radiographic changes Treatment A 50 year-old obese white female comes to your office with a chief
Speaking Plainly. Biologic treatment options for rheumatoid arthritis
in association with Plain English Campaign Speaking Plainly Biologic treatment options for rheumatoid arthritis A guide to help healthcare professionals talking to patients with rheumatoid arthritis Foreword
2015 Billing Guide for. REMICADE (infliximab)
2015 Billing Guide for REMICADE (infliximab) Table of Contents Introduction... 1 Factors That Influence Coverage.... 2 REMICADE (infliximab) Quick Reference Guide... 3 Coding for REMICADE and Drug Administration
ACTEMRA. Step Therapy Criteria HEALTH CHOICE EXCHANGE 2016 Effective Date: 01/01/2016. PRODUCT(s) AFFECTED ACTEMRA
ACTEMRA ACTEMRA Claim will pay automatically for Actemra if enrollee has a paid claim for at least a 1 days supply of Enbrel and Humira in the past 365 days. Otherwise, Actemra requires a step therapy
Medicines for Psoriatic Arthritis. A Review of the Research for Adults
Medicines for Psoriatic Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have psoriatic (pronounced
Biologics... The Story So Far. Biologics. The Story So Far. A Patient Guide to Biologic Therapies in the Treatment of Rheumatoid Arthritis
Biologics... The Story So Far Biologics The Story So Far A Patient Guide to Biologic Therapies in the Treatment of Rheumatoid Arthritis September 2013 Help & information from NRAS NRAS is the only patient-led
Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
Rheumatoid Arthritis. How are joints in the body designed?
Rheumatoid Arthritis How are joints in the body designed? There are more than 100 joints that connect the body s 206 bones. These joints allow us to move the way we do when we walk to work, throw a ball
Medications Guide March 2015
s Guide March 2015 Arthritis Consumer Experts (ACE) members/patients-at-large consistently request evidence-based information to enable them to have a more meaningful conversation with their rheumatologist
Patient Assistance Application for HUMIRA (adalimumab)
The AbbVie Patient Assistance Foundation provides AbbVie medicines at no cost to patients experiencing financial difficulties. Eligible patients typically have no healthcare coverage for the requested
2016 BlueCare Plus (HMO SNP) Provider Attestation Form
2016 BlueCare Plus (HMO SNP) Provider Attestation Form Provider Name Contract Entity/Group Name Patient Preventive Screenings Breast Cancer Screening The Breast Cancer Screening quality measure focuses
PSORIATIC ARTHRITIS. » Diagnosis» Symptoms» Treatments» + more
PSORIATIC ARTHRITIS» Diagnosis» Symptoms» Treatments» + more WHAT IS PSORIASIS? PSORIASIS is pronounced sore-eye-ah-sis. It is an autoimmune disease, meaning that certain triggers cause the immune system
Arthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis
Arthritis and Rheumatology Clinics of Kansas Patient Education Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis Introduction: For as long as scientists have studied rheumatic disease,
PRODUCT MONOGRAPH. HUMIRA adalimumab 40 mg in 0.8 ml sterile solution (50 mg/ml) subcutaneous injection
PRODUCT MONOGRAPH Pr HUMIRA adalimumab 40 mg in 0.8 ml sterile solution (50 mg/ml) subcutaneous injection Biological Response Modifier HUMIRA (adalimumab) treatment should be initiated and supervised by
The Janssen Biotech Support System. Getting patients started on STELARA
The Janssen Biotech Support System Getting patients started on STELARA 3 STEPS after identifying patients appropriate for STELARA (ustekinumab) STEP 1: Determine the correct dose STELARA is administered
Treating the Symptoms of Rheumatoid Arthritis: The Biologics. Comparing Effectiveness, Safety, Side Effects, and Price
Treating the Symptoms of Rheumatoid Arthritis: The Biologics Comparing Effectiveness, Safety, Side Effects, and Price Our Recommendations Injectable drugs referred to as biologic DMARDs (Disease-Modifying
Do I need a physician referral? Yes, we see patients on referral from a health care provider.
FAQS FOR OFFICE POLICIES How do I get an appointment? New appointments are made by physician referral only. Your referring health care provided will call for the appointment for you. What do I need to
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Remicade 100 mg powder for concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains
Using Biologics to Treat: Rheumatoid Arthritis. Comparing Effectiveness, Safety, Side Effects, and Price
Using Biologics to Treat: Rheumatoid Arthritis Comparing Effectiveness, Safety, Side Effects, and Price Contents Our Recommendations........................................... 3 Welcome....................................................
Shared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)
Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis
White Paper March 2013 Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis Catherine Augustyn, Brigham Walker, and Thomas F. Goss, PharmD Boston Healthcare Associates, Inc., Boston,
Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis
White Paper March 2013 Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis Catherine Augustyn, Brigham Walker, and Thomas F. Goss, PharmD Boston Healthcare Associates, Inc., Boston,
HIGHLIGHTS OF PRESCRIBING INFORMATION
HUMIRA - adalimumab injection, solution Abbott Laboratories ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively.
Understanding specialty drugs
Group Benefits Understanding specialty drugs What your pharmaceutical benefits plan may look like over the next decade Between 2011 and 2014, the percentage of total drug spend represented by specialty
Towards a New Model of Delivery of Care
Towards a New Model of Delivery of Care What can we do Different to Provide Better Delivery of Care? Algis Jovaisas, MD,FRCPC Division of Rheumatology University of Ottawa Current Modelsurrent Private
How To Take Methotrexate By Injection
How To Take Methotrexate By Injection 1 how long does it take for methotrexate to work for abortion 2 methotrexate 15 mg hair loss 3 methotrexate injection dosage for rheumatoid arthritis 4 order methotrexate
INDEX Note: PsA stands for psoriatic arthritis. Page numbers in italics indicate figures. Page numbers followed by a t indicate tables. Clinical trials and studies are indexed under the acronym of the
Original Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
Prior Authorization Guideline
Prior Authorization Guideline Guideline: Enbrel Therapeutic Class: Miscellaneous Therapeutic Agents Therapeutic Sub-Class: Disease-modifying Antirheumatic Drugs Client: 2007 AARP Medicare Rx Inj, 2007
Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy
Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy R Adams 1, Ct Ng 2, A Gibbs 2, L Tilson 1, D Veale 2, B Bresnihan 2, O FitzGerald 2, M Barry 1 1. National Centre for
Rheumatoid Arthritis: Constantly Evolving Treatment Approaches
Rheumatoid Arthritis: Constantly Evolving Treatment Approaches Jody Garry, Pharm.D. Primary Care Pharmacy Resident VA Medical Center - Iowa City Presentation Overview Pathophysiology & epidemiology Diagnostic
Can Rheumatoid Arthritis treatment ever be stopped?
Can Rheumatoid Arthritis treatment ever be stopped? Robert L. DiGiovanni, DO, FACOI Program Director Largo Medical Center Rheumatology Fellowship robdsimc@tampabay.rr.com Do not pour strange medicines
Disclosures. None. Seth Compton, MD Fellow of Rheumatology University of Mississippi Medical Center. Thank you for coming
Disclosures None Seth Compton, MD Fellow of Rheumatology University of Mississippi Medical Center Steroids Steroids Thank you for coming 1 Outline Osteoarthritis Rheumatoid Arthritis Monoarthritis Systemic
(CIM-zee-uh) HIGHLIGHTS OF PRESCRIBING INFORMATION WARNING: SERIOUS INFECTIONS AND MALIGNANCY
(CIM-zee-uh) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CIMZIA safely and effectively. See full prescribing information for CIMZIA. CIMZIA (certolizumab
Issue date: August 2010
Issue date: August 2010 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Part review of NICE technology appraisal
Multiple Sclerosis Step Therapy and Quantity Limit Criteria
Multiple Sclerosis Step Therapy and Quantity Limit Criteria Tysabri (natalizumab) will NOT be included in this step therapy program for Blue Cross and Blue Shield of Illinois because this plan does not
Order Phenytoin dilantin ivpb rate when to order phenytoin level dilantin 30 mg
Order Phenytoin 1 dilantin loading dose iv 2 can you buy dilantin 3 generic phenytoin manufacturers 4 what is a high dilantin level 5 buy generic dilantin 6 dilantin ivpb administration 7 purchase phenytoin
Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: 03/11/2014
Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: 03/11/2014 Board Members: Present: Joseph Lasek, MD, Chair Gary Starecheski, RPh Mark Pasanen, MD James
RESEARCH DIAGNOSTICS PHARMACEUTICALS
RESEARCH DIAGNOSTICS PHARMACEUTICALS Therapeutic drug monitoring is vitally important to optimize therapy for all patients treated with biologicals. Routine measurement of serum drug levels brings both
ACTEMRA Lab Monitoring Guide 1 For DMARD-IR patients with moderate to severe RA
ath,, interrupt er p infusion es including ld ACTEMRA Lab Monitoring Guide 1 For DMARD-IR patients with moderate to severe RA eving an d laboratory n training and death, permanently s, platelets, d Indication
Autoimmune Diseases More common than you think Randall Stevens, MD
Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system